ValiRx Share News (VAL)

TRADING UPDATES: FireAngel signs with British Gas; Shanta pours gold

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

TRADING UPDATES: Ediston signs 10-year lease with Marks & Spencer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

ValiRx incorporates new wholly-owned lab subsidiary

(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.

TRADING UPDATES: Somero revenue short of outlook; SigmaRoc optimistic

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: Future Metals in JV; Gunsynd sells stake in investee

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

IN BRIEF: ValiRx seeks up to GBP1.5 million for new research facility

ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Raises GBP1 million from placing of 9.1 million shares at 11 pence each. Also will raise up to GBP500,000 more from a broker offer to retail investors at the same price. Turner Pope Investments Ltd will run the broker offer. Every four shares in the placing and retail offer come with a warrant to buy another new share at 14p over the next three years. Calls February 2 general meeting to approve the fund raise. Currently has a GBP10.1 million market capitalisation.

ValiRx shares fall on test extension, but optimistic of other assets

(Alliance News) - ValiRx PLC on Tuesday saw shares drop, after extending its evaluation agreement with Hokkaido University to conduct further experimental testing.

ValiRx forms new majority-owned breast cancer subsidiary

(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property licence agreement with King's College London (KCL).

ValiRx teams with King's College London for cancer project

(Alliance News) - ValiRx PLC on Monday said it is making progress on its goal to introduce new academic projects into its portfolio, after launching subsidiary company Cytolytix Ltd and signing a licence agreement with King's College London.

IN BRIEF: ValiRx shares up on new interim chief scientific officer

ValiRx PLC - Nuneaton, England-based drug development company - Appoints Catherine Tralau-Stewart as interim chief scientific officer. Says she has experience working across leading pharmaceutical companies and academic groups. Tralau-Stewart will review new, incoming science; enhance the progress of existing projects; and influence the overall strategic scientific direction of the company, ValiRx adds. Chief Executive Suzy Dilly comments: "I'm looking forward to having another in-house scientist with whom to share ideas and to develop and deliver upon our strategic ambitions. Cathy's wealth of experience in exactly the areas in which we wish to progress, makes her an excellent choice for this role."

EARNINGS UPDATES: Windward widens loss as operating expenses rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

IN BRIEF: ValiRx shares jump on breast cancer drug candidate progress

ValiRx PLC - Nuneaton, England-based drug development company - Completes the evaluation of the impact of a peptide drug candidate against triple negative breast cancer. Evaluation concludes there is "good evidence" of biological activity and a "strong" rationale for further development. Adds that the drug candidate was investigated over nine months. Tests also demonstrate promising data on ovarian cancer cells, in addition to the targeted breast cancer cells. As a result, ValiRx has notified the academic team and intellectual property & licensing team at King's College London that it wants to proceed to full in-licensing.

IN BRIEF:ValiRx gains GBP1.0 million from Turner Pope broker option

ValiRx PLC - Nuneaton, England-based drug development company - Announces that the broker option granted to Turner Pope Investments Ltd has been fully subscribed and raises GBP1.0 million before expenses.

TRADING UPDATES: M&C Saatchi expects to deliver on annual profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: